Loading
A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk is a phase 3 interventional study registered as NCT06468033 by PharmaEssentia, with 160 participants enrolled, started 2025-07-18 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ropeginterferon alfa-2b, Placebo. Conditions listed: Primary Myelofibrosis, Myeloproliferative Neoplasm. No results are recorded here; the registry entry is the source.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Ropeginterferon alfa-2b, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).